M&A Deal Summary

Kyowa Kirin Acquires Orchard Therapeutics

On October 5, 2023, Kyowa Kirin acquired life science company Orchard Therapeutics for 478M USD

Acquisition Highlights
  • This is Kyowa Kirin’s 1st transaction in the Life Science sector.
  • This is Kyowa Kirin’s largest (disclosed) transaction.
  • This is Kyowa Kirin’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2023-10-05
Target Orchard Therapeutics
Sector Life Science
Buyer(s) Kyowa Kirin
Deal Type Add-on Acquisition
Deal Value 478M USD
Advisor(s) Guggenheim Securities (Financial)
Goodwin Procter
Slaughter and May (Legal)

Target

Orchard Therapeutics

London, United Kingdom
Orchard Therapeutics is a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. Orchard Therapeutics was founded in 2015 and is based in London, United Kingdom.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Kyowa Kirin

Tokyo, Japan
Category Company
Sector Life Science
DESCRIPTION

Kyowa Kirin is a global specialty pharmaceutical company (J-GSP) that creates innovative medical solutions utilizing the latest biotechnology. The company applies cutting-edge science including expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including nephrology, oncology, immunology/allergy, and nurology. Kyowa Kirin is based in Tokyo.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (United Kingdom) 1 of 1
Year (2023) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal